SciVision Biotech Inc. (1786.TW)
TWD 96.3
(-0.82%)
TWD 96.3
(-0.82%)
| Year | Total Liabilities | Total Liabilities Growth |
|---|---|---|
| 2023 | 533.66 Million TWD | -9.13% |
| 2022 | 587.3 Million TWD | -27.68% |
| 2021 | 812.06 Million TWD | 66.9% |
| 2020 | 486.54 Million TWD | -2.9% |
| 2019 | 501.08 Million TWD | -18.88% |
| 2018 | 617.7 Million TWD | -4.78% |
| 2017 | 648.71 Million TWD | 40.13% |
| 2016 | 462.92 Million TWD | 272.86% |
| 2015 | 124.15 Million TWD | 80.43% |
| 2014 | 68.81 Million TWD | 52.13% |
| 2013 | 45.23 Million TWD | -21.07% |
| 2012 | 57.3 Million TWD | 42.67% |
| 2011 | 40.16 Million TWD | -63.89% |
| 2010 | 111.23 Million TWD | 6.64% |
| 2009 | 104.31 Million TWD | 0.0% |
| Year | Total Liabilities | Total Liabilities Growth |
|---|---|---|
| 2024 Q1 | 716.58 Million TWD | 34.28% |
| 2024 Q2 | 632.94 Million TWD | -11.67% |
| 2023 Q4 | 533.66 Million TWD | -4.98% |
| 2023 Q3 | 561.61 Million TWD | -18.26% |
| 2023 FY | 533.66 Million TWD | -9.13% |
| 2023 Q1 | 545.01 Million TWD | -7.2% |
| 2023 Q2 | 687.09 Million TWD | 26.07% |
| 2022 FY | 587.3 Million TWD | -27.68% |
| 2022 Q4 | 587.3 Million TWD | -34.76% |
| 2022 Q3 | 900.25 Million TWD | 51.77% |
| 2022 Q2 | 593.16 Million TWD | 18.78% |
| 2022 Q1 | 499.38 Million TWD | -38.5% |
| 2021 FY | 812.06 Million TWD | 66.9% |
| 2021 Q2 | 820.12 Million TWD | 3.04% |
| 2021 Q4 | 812.06 Million TWD | -5.76% |
| 2021 Q1 | 795.9 Million TWD | 63.58% |
| 2021 Q3 | 861.68 Million TWD | 5.07% |
| 2020 Q3 | 494.52 Million TWD | -15.19% |
| 2020 FY | 486.54 Million TWD | -2.9% |
| 2020 Q4 | 486.54 Million TWD | -1.61% |
| 2020 Q1 | 490.75 Million TWD | -2.06% |
| 2020 Q2 | 583.09 Million TWD | 18.81% |
| 2019 Q4 | 501.08 Million TWD | 4.62% |
| 2019 Q1 | 503.45 Million TWD | -18.5% |
| 2019 FY | 501.08 Million TWD | -18.88% |
| 2019 Q3 | 478.93 Million TWD | -18.23% |
| 2019 Q2 | 585.68 Million TWD | 16.33% |
| 2018 Q2 | 678.93 Million TWD | 3.18% |
| 2018 Q1 | 657.99 Million TWD | 1.43% |
| 2018 FY | 617.7 Million TWD | -4.78% |
| 2018 Q4 | 617.7 Million TWD | -6.39% |
| 2018 Q3 | 659.84 Million TWD | -2.81% |
| 2017 Q1 | 456.61 Million TWD | -1.36% |
| 2017 Q3 | 667.05 Million TWD | 7.91% |
| 2017 Q4 | 648.71 Million TWD | -2.75% |
| 2017 FY | 648.71 Million TWD | 40.13% |
| 2017 Q2 | 618.16 Million TWD | 35.38% |
| 2016 Q2 | 356 Million TWD | 19.86% |
| 2016 Q1 | 297.01 Million TWD | 139.22% |
| 2016 FY | 462.92 Million TWD | 272.86% |
| 2016 Q3 | 443.48 Million TWD | 24.57% |
| 2016 Q4 | 462.92 Million TWD | 4.39% |
| 2015 Q4 | 124.15 Million TWD | -17.68% |
| 2015 FY | 124.15 Million TWD | 80.43% |
| 2015 Q3 | 150.81 Million TWD | 114.45% |
| 2015 Q2 | 70.32 Million TWD | -16.95% |
| 2015 Q1 | 84.68 Million TWD | 23.07% |
| 2014 Q3 | 45.02 Million TWD | -6.42% |
| 2014 Q2 | 48.11 Million TWD | -3.7% |
| 2014 Q1 | 49.96 Million TWD | 10.47% |
| 2014 FY | 68.81 Million TWD | 52.13% |
| 2014 Q4 | 68.81 Million TWD | 52.81% |
| 2013 Q4 | 45.23 Million TWD | -26.17% |
| 2013 Q1 | 59.5 Million TWD | 3.84% |
| 2013 FY | 45.23 Million TWD | -21.07% |
| 2013 Q3 | 61.26 Million TWD | -6.69% |
| 2013 Q2 | 65.66 Million TWD | 10.34% |
| 2012 FY | 57.3 Million TWD | 42.67% |
| 2012 Q3 | 53.65 Million TWD | 4.28% |
| 2012 Q2 | 51.45 Million TWD | 0.0% |
| 2012 Q4 | 57.3 Million TWD | 6.81% |
| 2011 Q4 | 40.16 Million TWD | 0.0% |
| 2011 Q2 | 37.97 Million TWD | 0.0% |
| 2011 FY | 40.16 Million TWD | -63.89% |
| 2010 Q4 | 111.23 Million TWD | 0.0% |
| 2010 FY | 111.23 Million TWD | 6.64% |
| 2009 FY | 104.31 Million TWD | 0.0% |
| Name | Total Liabilities | Total Liabilities Difference |
|---|---|---|
| Nang Kuang Pharmaceutical Co., Ltd. | 1.47 Billion TWD | 63.919% |
| Maxigen Biotech Inc. | 131.88 Million TWD | -304.65% |
| Bionime Corporation | 3.3 Billion TWD | 83.864% |
| Pegavision Corporation | 3.87 Billion TWD | 86.24% |
| Visco Vision Inc. | 1.74 Billion TWD | 69.357% |